Inventor · disambiguated record
Anil Kumar
Also filed as: KUMAR ANIL · KUMAR ANIL M
39 granted patents·15 pending applications·688 citations·filing 1993–2024
98Inventor score
Files withCELL THERAPEUTICS INC34MANKIND PHARMA LTD10INT PAPER CO3COUNCIL SCIENT IND RES1DIKSHIT DINESH KUMAR1
Top patents by PatentIndex Score
54 records- 0196US7618968B2Aryl triazines as LPAAT-β inhibitors and uses thereofCELL THERAPEUTICS INC·Filed 2007·Granted Nov 17, 2009·24 cites·12 claims
- 0295US6878715B1Therapeutic compounds for inhibiting interleukin-12 signals and method for using sameCELL THERAPEUTICS INC·Filed 2000·Granted Apr 12, 2005·46 cites·6 claims
- 0395US5807861AAmine substituted xanthinyl compoundsCELL THERAPEUTICS INC·Filed 1995·Granted Sep 15, 1998·106 cites·21 claims
- 0495US5641783ASubstituted amino alcohol compoundsCELL THERAPEUTICS INC·Filed 1994·Granted Jun 24, 1997·57 cites·22 claims
- 0590US5670506AHalogen, isothiocyanate or azide substituted xanthinesCELL THERAPEUTICS INC·Filed 1993·Granted Sep 23, 1997·43 cites·17 claims
- 0689US5837703AAmino-alcohol substituted cyclic compoundsCELL THERAPEUTICS INC·Filed 1993·Granted Nov 17, 1998·33 cites·9 claims
- 0789US5801182AAmine substituted compoundsCELL THERAPEUTICS INC·Filed 1995·Granted Sep 1, 1998·50 cites·16 claims
- 0887US7291616B2Aryl triazines as LPAAT-β inhibitors and uses thereofCELL THERAPEUTICS INC·Filed 2002·Granted Nov 6, 2007·26 cites·2 claims
- 0985US10208030B2GPR119 agonist compoundsMANKIND PHARMA LTD·Filed 2017·Granted Feb 19, 2019·11 cites·26 claims
- 1085US6020337AElectronegative-substituted long chain xanthine compoundsCELL THERAPEUTICS INC·Filed 1997·Granted Feb 1, 2000·36 cites·17 claims
- 1185US5807862ATherapeutic compounds containing pyrimidinyl moietiesCELL THERAPEUTICS INC·Filed 1995·Granted Sep 15, 1998·53 cites·6 claims
- 1279US6469017B1Method of inhibiting interleukin-12 signalingCELL THERAPEUTICS INC·Filed 1998·Granted Oct 22, 2002·17 cites·11 claims
- 1379US5777117AMethod for preparing substituted amino alcohol compoundsCELL THERAPEUTICS INC·Filed 1995·Granted Jul 7, 1998·15 cites·22 claims
- 1475US9169255B2Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathiesPROTEOTECH INC·Filed 2012·Granted Oct 27, 2015·4 cites·13 claims
- 1574US5866576AEpoxide-containing compoundsCELL THERAPEUTICS INC·Filed 1997·Granted Feb 2, 1999·15 cites·9 claims
- 1672US2024239803A1Synthesis of coelenterazineINT PAPER CO·Filed 2024·Application pending·0 cites
- 1770US6780865B1Compounds having selective hydrolytic potentialsCELL THERAPEUTICS INC·Filed 1997·Granted Aug 24, 2004·12 cites·21 claims
- 1868US11939332B2Synthesis of coelenterazineINT PAPER CO·Filed 2020·Granted Mar 26, 2024·0 cites·9 claims
- 1968US6075029AXanthine modulators of metabolism of cellular P-450CELL THERAPEUTICS INC·Filed 1998·Granted Jun 13, 2000·12 cites·14 claims
- 2067US11008326B2Synthesis of coelenterazineINT PAPER CO·Filed 2019·Granted May 18, 2021·0 cites·10 claims
- 2167US7399860B2Manufacture of polyglutamate-therapeutic agent conjugatesCELL THERAPEUTICS INC·Filed 2003·Granted Jul 15, 2008·4 cites·25 claims
- 2267US6103730AAmine substituted compoundsCELL THERAPEUTICS INC·Filed 1995·Granted Aug 15, 2000·13 cites·7 claims
- 2367US5629423AAsymmetric synthesis of chiral secondary alcoholsCELL THERAPEUTICS INC·Filed 1995·Granted May 13, 1997·21 cites·30 claims
- 2466US6774130B2Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using sameCELL THERAPEUTICS INC·Filed 1999·Granted Aug 10, 2004·22 cites·26 claims
- 2566US6693105B1Hydroxyl-containing compoundsCELL THERAPEUTICS INC·Filed 1999·Granted Feb 17, 2004·11 cites·18 claims
- 2663US2025051358A1Processes for the preparation and purification of gpr119 agonist compounds and intermediates thereofMANKIND PHARMA LTD·Filed 2024·Application pending·0 cites
- 2763US2025051357A1Solid forms of a gpr119 agonist and processes for the preparation thereofMANKIND PHARMA LTD·Filed 2024·Application pending·0 cites
- 2862US10919915B2Compounds as GPR119 agonistsMANKIND PHARMA LTD·Filed 2019·Granted Feb 16, 2021·0 cites·15 claims
- 2962US2025049794A1Pharmaceutical formulations of gpr119 agonists and uses thereofMANKIND PHARMA LTD·Filed 2024·Application pending·0 cites
- 3059US10752622B2GPR119 agonist compoundsMANKIND PHARMA LTD·Filed 2018·Granted Aug 25, 2020·0 cites·5 claims
- 3159US7053096B2Compounds having selective hydrolytic potentialsCELL THERAPEUTICS INC·Filed 2004·Granted May 30, 2006·1 cites·19 claims
- 3259US6100271ATherapeutic compounds containing xanthinylCELL THERAPEUTICS INC·Filed 1995·Granted Aug 8, 2000·12 cites·14 claims
- 3359US2025388564A1Methods of manufacturing pyridazinone compoundsEDGEWISE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3458US6043250AMethods for using therapeutic compounds containing xanthinylCELL THERAPEUTICS INC·Filed 1995·Granted Mar 28, 2000·12 cites·6 claims
- 3558US2006211713A1Compounds having selective hydrolytic potentialsCELL THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3657US5756511AMethod for treating symptoms of a neurodegenerative conditionCELL THERAPEUTICS INC·Filed 1995·Granted May 26, 1998·19 cites·5 claims
- 3756US5750575ASubstituted amino alcohol compoundsCELL THERAPEUTICS INC·Filed 1995·Granted May 12, 1998·4 cites·18 claims
- 3854US2005032748A1Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using sameCELL THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 3952US2003207901A1Hydroxyl-containing compoundsCELL THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 4051US2004002526A1Phospholipase D inhibitors and uses thereofCELL THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 4151US2005049262A1Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using sameCELL THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 4250US6121270AEpoxide-containing compoundsCELL THERAPEUTICS INC·Filed 1998·Granted Sep 19, 2000·3 cites·9 claims
- 4349US10954229B2GPR119 agonist compoundsMANKIND PHARMA LTD·Filed 2020·Granted Mar 23, 2021·0 cites·7 claims
- 4449US9687480B2Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl)-pyrrolidine as inhibitors of collagen induced platelet activation and adhesionCOUNCIL SCIENT IND RES·Filed 2015·Granted Jun 27, 2017·0 cites·15 claims
- 4549US7799753B2Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agentsGOVERNERS FOR HIGHER EDUCATION·Filed 2006·Granted Sep 21, 2010·0 cites·24 claims
- 4646US9206155B2Chiral 1-(4-methylphenylmethyl)-5-OXO-{N-[3-T-butoxycarbonyl-aminomethyl)]-piperidin-1-yl-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesionDIKSHIT DINESH KUMAR·Filed 2012·Granted Dec 8, 2015·0 cites·13 claims
- 4746US2003054977A1Manufacture of polyglutamate-therapeutic agent conjugatesCELL THERAPEUTICS INC·Filed 2002·Application pending·0 cites
- 4843US5521315AOlefin substituted long chain compoundsCELL THERAPEUTICS INC·Filed 1993·Granted May 28, 1996·5 cites·7 claims
- 4942US10526345B2Compounds as GPR119 agonistsMANKIND PHARMA LTD·Filed 2017·Granted Jan 7, 2020·0 cites·27 claims
- 5042US2022332700A1Novel apoptosis signal-regulating kinase 1 inhibitorsMANKIND PHARMA LTD·Filed 2020·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Anil Kumar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →